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1. Introduction 
Current controversy exists regarding the role of chemopreventative agents for prostate 
cancer. However, prostate cancer’s role in our society remains prevalent. Prostate cancer 
continues to be the leading cause of newly diagnosed male cancers in the United States. In 
2011, the American Cancer Society estimated 241,740 new cases and 28,170 deaths from 
prostate cancer.1 Only lung cancer has more male cancer deaths. Current treatment 
strategies such as surgery, radiation, chemotherapy and hormone therapies have been 
successful in decreasing prostate cancer related morbidity and mortality. However, the 
physician’s armamentarium is focused on treating existing prostate cancer and not 
preventing it. Despite the prolongation of life for patients with prostate cancer, each therapy 
carries a side effect profile.  
Due to improved early detection, prostate cancer is now often identified at an earlier stage 
and grade. Newly diagnosed tumors are often organ confined and slow growing. However, 
once a patient’s PSA laboratory value is abnormal, he will most likely receive a prostate 
biopsy for diagnosis. Given the fact that less than 10% of Americans select active 
surveillance, screening starts a snowball effect that usually “buys” a treatment. It is well 
known that treatment including radical prostatectomy or radiation has been shown to 
overtreat prostate cancer in as many as 30-50% of patients.2 Morbidity, including 
incontinence and impotence can significantly affect a patient’s quality of life. In addition, the 
knowledge of prostate cancer may cause emotional, financial and physical harm.3,4 Given 
that the US male population faces a 16.7% lifetime risk of prostate cancer, prostate cancer is 
an ideal candidate for prevention strategies.  
Cancer chemoprevention focuses on the use of natural or synthetic agents to suppress, 
delay, or prevent the development of tumors. Natural substances have long been utilized 
with varying results for prostate cancer prevention. More recently in the 2000s, 5-alpha 
reductase inhibitors (5-ARI) have also been used. These substances have focused on both 
primary prevention and secondary prevention. Primary prevention focuses on deferring or 
preventing the presence of cancer prior to cancer formation. Secondary prevention focuses 
on preventing premalignant lesions from progressing to cancer. For prostate cancer, 
secondary prevention focuses on preventing the progression of high grade prostate 
epithelial neoplasia (HGPIN).  
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In December of 2010, the Federal Drug Administration’s (FDA) Oncology Drugs Advisory 
Committee (ODAC) reviewed 5-ARI’s indication for the prevention of prostate cancer in 
men at increased risk for prostate cancer. This committee ruled against the use of 5-ARI’s for 
the use of prostate chemoprevention. Advocacy groups have since issues statements 
disagreeing with the FDA’s ruling, highlighting the fact that controversy continues to exist. 
The goal of this paper is to examine the available agents and the current environment.  
2. Current chemopreventative agents - pharmaceuticals and micronutrients 
The ideal chemopreventative agent should be minimally expensive, nontoxic and effective. 
Having multiple preventative benefits is considered a plus; however it should not potentiate 
other causes of morbidity or mortality. Pharmaceutical agents, most notably 5-ARIs, and 
micronutrients have been studied to better establish their potential role in cancer 
prevention. 
2.1 Pharmaceuticals 
Finasteride and dutasteride are both 5-ARI medications used to successfully inhibit prostate 
growth. These two agents are both currently accepted for treating benign prostatic 
hypertrophy (BPH). The difference between the two medications is minimal, however 
potentially significant. 5-α-Reductase has two isoenzymes. Finasteride inhibits the type 2 
isoenzyme while dutasteride inhibits both the type 1 and type 2 isoenzymes. Dutasteride 
thus has more complete inhibition of DHT, roughly 90% as compared to finasteride’s 70% 
reduction of serum DHT.5,6 It has been proposed that expression of the type 1 isoenzyme is 
increased with prostate cancer while the type 2 isoenzyme is unaffected with prostate 
cancer.7 5-ARI medications focus on inhibiting androgen receptor (AR) activation. Research 
on BPH has shown that consistent use of finasteride or dutasteride decreases prostatic 
volume 30% and reduce PSA levels 50-60%.8 Both 5-ARI medications have been tested for 
chemopreventative benefits with multicenter, randomized, double blind, placebo controlled 
trials. The thrust of this paper will discuss the 5-ARI medications and their current role in 
prostate cancer prevention. 
Other pharmaceutical agents potentially used for prostate cancer prevention include statins, 
nonsteroidal anti-inflammatory drugs (NSAIDS), and toremifene. Statins inhibit HMG-CoA, 
the rate limiting step of cholesterol synthesis. Statin use over 2 years has been associated 
with a decrease in prostate specific antigen.9 By inhibiting prostatic cellular growth and 
promoting apoptosis, statins also decrease cellular growth. No large double blind study has 
evaluated the effect of statin use on prostate cancer but a meta-analysis did find a protective 
effect.10 Further studies are needed to substantiate current evidence.  
NSAIDS inhibit cyclooxygenase-2 (COX-2), which is a key enzyme found in prostate cancer 
which converts arachidonic acid to prostaglandins. Experimental evidence demonstrated a 
regression of PIN after NSAID use, but the planned trial with rofecoxib was withdrawn 
after safety concerns.11,12 
Selective estrogen modulators (SERMs) are best known for their effects on breast cancer. 
Toremifene has decreased prostate cancer in the TRAMP model. A phase 2b study found 
that 20mg doses of toremifene resulted in a 48% decrease in prostate cancer at one year.13 
However, the phase III trial demonstrated no significant risk reduction.14 
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Micronutrients have long been sought after to provide a chemotherapeutic benefit for the 
development or prevention of prostate cancer. Antioxidants in vitro can inhibit cellular 
proliferation, induce apoptosis and modulate genes leading to the suppression of prostatic 
tumor. 15,16 The largest scale trial on micronutrients was for selenium and vitamin E in the 
Selenium and Vitamin E Cancer Prevention Trial (SELECT).  
The interest in selenium began with the Nutritional Prevention of Cancer Trial, which used 
oral selenium for nonmelanoma skin cancer. Men were randomized to selenium versus 
placebo and were found to have a 65% reduction in prostate cancer incidence after a 4.5 year 
follow up. Vitamin E interest developed after a 32% reduction in prostate cancer in the 
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Trial (ATBC) trial, which was a double 
blind randomized placebo controlled trial for lung cancer incidence and mortality.  
These studies paved the way for the SELECT trial, published in 2009, which was a 
randomized, placebo controlled population based primary prevention trial focused on the 
effects of selenium and vitamin E on preventing prostate cancer. SELECT randomized 
35,533 men to four treatment arms: selenium with placebo, selenium with vitamin E, 
Vitamin E with placebo, placebo with placebo. Study supplements included 200 micrograms 
l-selenomethionine, 400mg racemic alpha-tocopherol and an optional multivitamin 
containing no selenium or vitamin E. Eligible men were at least 50 years of age for African-
Americans, at least 55 for Caucasians, negative DRE, PSA less than 4ng/mL, and normal 
blood pressure.  
The primary endpoint was the presence of prostate cancer found on for cause biopsies. The 
indications for biopsy were not indicated in the protocol and were at the discretion of the 
physician.  
During the second interim analysis seven years after initiation of the trial, the independent 
Data and Safety Monitoring Committee recommended discontinuation of the SELECT 
because the data demonstrated no significant differences between groups. No statistically 
significant effects were reported on primary or secondary analyses of the data, suggesting 
no prostate cancer prevention benefits from selenium or vitamin E.17 Unfortunately, 
selenium and vitamin E, which initially demonstrated promise, was eventually found to not 
have a significant effect on preventing prostate cancer. 17-19  
Other chemopreventative micronutrients include lycopene, green tea, soy, DIM and 
curcumin. Molecular targets these agents affect include nuclear factor-KB, AKt, Wnt, 
Hedgehog and Notch.20 
Lycopene is a biologically occurring carotenoid that is a potent antioxidant. It has been 
shown to be associated with lower prostate cancer risk in a number of epidemiologic 
studies.21 Using the preclinical TRAMP mouse model, prostate cancer was significantly 
decreased 60% vs. 95% (P=.01). However, no correlation was found with prostate cancer in a 
PLCO trial examining 29,000 men.  
Green tea contains several catechins believed to inhibit oncogenesis and provide 
antioxidants. Epidemiologic studies between Asian men with a high intake of green tea first 
suggested that green tea may provide a protective benefit against prostate cancer. Three 
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clinical trials suggest a benefit.22 A small clinical trial (n=60) using oral green tea catechins 
(GTC) found that patients with HGPIN randomized to GTC vs. placebo had no change in 
PSA levels, but did have less progression of prostate cancer: 1 patient vs. 9 patients 
progress.23  
Soy, like green tea, was also found to demonstrate lower prostate cancer in epidemiologic 
studies between diets high in soy versus western diets. The benefit is potentially a 70% 
reduction of prostate cancer.24 Soy affects signaling pathways, specifically Wnt and Hh 
signaling. Randomized studies are currently being performed.  
DIM (the dimeric product of indole-3-carbinol) is found in a variety of plants and has been 
shown to inhibit alpha reductase suggesting that it may have an inhibitory role in prostate 
cancer. Curcumin is a bioavailable agent in turmeric and is also an alpha reductase inhibitor. 
Other regulators along the tumor pathway are inhibited by these two substances. Clinical 
trials are required to evaluate their effects.  
Currently no biologically available micronutrients have been proven to provide 
chemoprevention benefits of prostate cancer. As such, current patient recommendations are 
to eat healthy foods and pursue healthy lifestyle changes.25 
3. Review of 5-ARI chemoprevention trials 
We reviewed the multicenter randomized double blind studies focused on 5-ARI usage 
versus placebo for prostate cancer chemoprevention including the Prostate Cancer 
Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events 
(REDUCE). Table 1 compares their study design.   
 
Trial Population Risk Category Agent Target Reported 
Prostate Cancer 
Prevention Trial (PCPT) n = 18,882 
PSA <3.0 ng/mL 
DRE Normal 
Finasteride  
(Merck) Type 1 5-ARI 2008 
Reduction by 
Dutasteride of Prostate 
Cancer Events Trial 





(GlaxoSmithKline) Type 1,2 5-ARI 2009 
Table 1. Comparison of PCPT & REDUCE trials. 
3.1 Prostate Cancer Prevention Trial (PCPT) 
The Prostate Cancer Prevention Trial was the first large multicenter randomized double 
blind prostate prevention trial using a 5-ARI. In 2003, 18,882 men, 55 years or older with a 
PSA level less than 3.0ng/mL and a normal digital rectal exam (DRE) were randomized for 
seven years to finasteride 5mg daily or placebo. 
Of the men who participated, 48%, or 9060 men were included in the final analysis. 
Enrollment criteria included men 55 years or older who were free of prostate cancer, no 
other significant co morbidities, and an American Urological Association symptom score 
(AUA-SS) of less than 20. Eligible participants were required to have a PSA less than 
3.0ng/ml, normal DRE, adherent to the study protocol and no side effects during placebo. 
Men were contacted every three months for medical event evaluation and were seen by the 
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study site every six months for side effect evaluation and medication refills. Annual PSA 
and DRE were performed. Biopsy was recommended if the DRE was abnormal or PSA was 
greater than 4.0ng/ml in the placebo arm or 2.0 times PSA (adjusted to 2.3x in year 4) in the 
finasteride arm. At the completion of the trial in year seven, all participants were 
recommended to undergo an end of study prostate biopsy with at least six cores. All 
biopsies were reviewed by a blinded pathologist.  
The primary endpoint of the study was the prevalence of prostate cancer as diagnosed by 
biopsy for cause or end of study biopsies. Prostate cancer was found in 24.4% of the placebo 
group (1,147/4,692) and 18.4% of the finasteride group (803/4,368), representing a 24.8% 
risk reduction (CI 19-31, p<0.001). Finasteride’s relative benefit was found across all groups 
including age, race/ethnicity, family history and entry PSA. In addition, Finasteride also 
reduced the risk of HGPIN compared to placebo. 
Interestingly, tumors with a Gleason grade of 7-10, high grade tumors, were found to be 
more prevalent in the finasteride group (37%), 280 of 757 graded tumors, as compared to the 
placebo group (22%), 237 of 1,068 graded tumors. This was statistically significant (P<.001). 
The increased prevalence of high grade tumors in the treatment group has generated 
tremendous speculation and sub-analysis. Forty of the excess high grade tumors were found 
in the “for cause” biopsies, clinically indicated due to increasing PSA or changes in the DRE.  
Secondary analyses have found a detection bias demonstrating a net reduction in high-
grade cancers and a 53% reduction in low grade cancers.26 However, due disagreement in 
the medical community regarding finasteride’s effect on high-grade cancers, it was not 
given a new indication for prostate cancer prevention. 
3.2 The Reduction by Dutasteride of Prostate Cancer Events (REDUCE) 
Published in the New England Journal of Medicine in April of 2010, the REDUCE trial, was a 4-
year multicenter, randomized, double-blind, placebo-controlled, parallel-group study. 8,231 
men were randomized equally to dutasteride 0.5mg daily versus placebo. This trial was 
begun prior to the completion of the PCPT trial. Eligible patients were randomized to 
receive either Dutasteride or placebo. There has never been a large randomized trial 
comparing finasteride to dutasteride for the prevention of prostate cancer.  
An important distinction between dutasteride and finasteride is the effect on 5-alpha 
reductase. Unlike finasteride, dutasteride affects the expression of both type 1 and type 2 
isoenzymes of 5-alpha reductase inhibitors. Animal studies demonstrate that compared to 
finasteride, dutasteride has an increased reduction in both DHT and tumor growth.27 
Dutasteride, then, theoretically could enhance the anti-tumor effect. 
Eligible participants were required to be 50-75 years old, have a serum PSA between 
2.5ng/mL-10mg/mL for men aged 50-60 years or 3.0-10ng/mL for men aged >60 years, and 
had undergone a prostate biopsy within six months of enrollment. Men were excluded if 
they had more than one biopsy, had prostate cancer of any grade, HGPIN, atypical small 
acinar proliferation, or a prostate volume of more than 80 grams, had previous prostate 
surgery of any kind, or had an international prostate symptom score (IPSS) of 25 or higher.  
During the trial 6726 men (82.6%) underwent at least 1 biopsy and 1516 men (22.5%) were 
diagnosed with prostate cancer. The primary endpoint was the presence of prostate cancer 
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detected on biopsy 2 or 4 years after treatment. Biopsies performed out of the protocol were 
considered protocol independent biopsies. Other important endpoints included Gleason 
score, tumor volume, percent of positive biopsy cores, presence of HGPIN, and presence of 
small acinar proliferation. BPH endpoints were also evaluated.  
The dutasteride arm represented an absolute risk reduction of 5% and a relative risk 
reduction of 23% (857 in the placebo arm versus 659 in the dutasteride arm, P<.001). This 
benefit was across all subgroups including age, family history, PSA level, prostate volume, 
or body mass index. The odds ratio for prostate cancer, detected on biopsy, with dutasteride 
as compared with placebo was 0.60 for all tumors (P<.001) and 0.62 for Gleason scores of 7 
to 10 (P<.001).  
Low grade tumors (Gleason 5, 6) were statistically higher in the placebo group (617 in 
placebo vs. 437 in dutasteride, P<0.001). The evidence of premalignant lesions was also 
decreased. HGPIN had a relative risk reduction of 39% (p<0.001) and small acinar 
proliferation (ASAP) had a relative risk reduction of 21% (p=0.04).  
For high grade tumors, REDUCE demonstrated no significant overall increase in Gleason 
score 7 to 10, high grade, cancers. This was different from the PCPT, which alarmingly 
showed an increase in high grade cancer. Overall, there were 220 tumors with a Gleason 
score of 7 to 10 among 3299 men in the dutasteride group and 233 among 3407 men in the 
placebo group (P=0.81).  
For the Gleason grade 8-10 tumors, there was no overall statistical difference looking at 
biopsies from all four years: 19 in placebo vs. 29 in dutasteride (P = .15). However, focusing 
on the second round of biopsies during years 3 and 4 of the study demonstrated a statistical 
increase in high grade tumors as compared to placebo. There were 12 tumors with a Gleason 
score of 8 to 10 in the dutasteride group, as compared with only 1 in the placebo group 
(P=0.003).28 The authors speculate that this was caused by more frequent early detection of 
low grade tumors in the placebo group that might have progressed if left untreated. As 
expected, dutasteride also demonstrated improved outcomes with BPH. Prostate volume, 
acute urinary retention and BPH related surgery, and urinary tract infections were all 
significantly reduced in the dutasteride group.  
The REDUCE trial, like the PCPT, demonstrated a significant effect on low grade cancers 
(Gleason 5, 6), but did not appear to alter the prevalence of high grade cancers. Overall it 
was well tolerated but did have significant effects on libido, erectile dysfunction, and semen 
volume.  
3.3 Controversy: high grade tumor risk and generalizability  
The effects of 5ARI’s on low grade cancer is consistent across both the PCPT and the 
REDUCE trials. However, each trial demonstrates a trend towards high grade disease. 
Initially, the authors from the PCPT concluded that the risk of finasteride on high grade 
tumors was uncertain. They recommended finasteride not be used as a chemopreventative 
agent.29  
Secondary analyses based on the PCPT data were then performed to better understand the 
conclusions drawn from the data. These authors concluded that biases due to prostate 
specific antigen (PSA), digital rectal exam (DRE), and prostate volume detection were 
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responsible for a trend towards increased detection of higher grade tumors found in the “for 
cause” biopsies for the finasteride arm of the PCPT trial. Consequently, the “end of study” 
biopsies showed no increased risk of high grade tumor.30 The increased sensitivity of digital 
rectal exam performed while a patient is on finasteride has also been shown to increase 
sensitivity for detecting nodules. Detection increased from 16% to 21% (P=.015).31 
Finally, PSA sensitivity for detecting prostate cancer increased with the use of 5-ARIs. Both 
finasteride and dutasteride reduce the PSA laboratory value by approximately half. 
Consequently, PSA performs better (is more sensitive) in detecting high grade tumors.32 For 
the PCPT, for cause biopsies due to a higher PSA level artificially selected for more biopsies 
to be taken from the treatment group. Prostate volume decreases with finasteride use thus 
allowed for a larger percentage of the gland to be sampled due to the ratio of the needle to 
the prostate.  The PCPT did not stratify on prostate volume size and it is unclear if this 
theoretical bias altered the trend towards high grade tumors. 
A reevaluation of the PCPT data adjusted for prostate sampling density and baseline PSA 
levels found that the finasteride group actually had a small net reduction in high grade 
cancers and a 53% decrease in low grade tumors.26 A subsequent analysis of the PCPT data 
using end point prostatectomy instead of prostate biopsy demonstrated a 16% reduction in 
high grade tumor. At the time of prostatectomy, significant upstaging of cancer was 
detected in the placebo group but not in the treatment group. In fact, the misclassification of 
true high-grade disease (to low-grade disease on biopsy) was significantly lower for 
finasteride (34.6%) than for placebo (52.6%).33 Finally, another study looking at 500 patients 
who underwent prostatectomy demonstrated a high-grade cancer rates of 8.2% (placebo) 
versus 6.0% (finasteride), a 27% risk reduction (RR, 0.73; 95% CI, 0.56-0.96; P = 0.02) with 
finasteride.34  The authors concluded that it finasteride probably does not cause high grade 
cancers, and may in fact improve the detection of them.  
The REDUCE trial proved that there was no overall difference for high grade tumors 
between dutasteride and placebo during the entire study. However subgroup analyses 
demonstrated a trend towards Gleason 8-10 tumors in the dutasteride group study (19 in 
placebo vs. 29 in dutasteride, P = .15). In addition the statistically significant increase of high 
grade tumors in years 3 and 4 was alarming (1 in placebo vs. 12 in dutasteride, P = .003). The 
authors of the study concluded that the increased number of high grade tumors was due to 
the increased detection bias in the dutasteride arm as well as removal of low grade cancer in 
years one and two in the placebo arm. Post hoc analyses similar to the ones performed on 
the PCPT are pending.  
3.4 Current political environment of 5-ARI 
In December of 2010, the Federal Drug Administration’s Oncology Drugs Advisory 
Committee (ODAC) reviewed 5-ARI’s indication for the prevention of prostate cancer in 
men at increased risk for prostate cancer. GlaxoSmithKline submitted an application to add 
prostate cancer prevention as an indication for dutasteride, and Merck submitted an 
application to alter the labeling for finasteride to reflect a more favorable safety profile with 
regard to preventing prostate cancer.  
ODAC analyzed the results from the PCPT and REDUCE trials. They concluded that the 
majority of cancers prevented were low risk, thus providing no evidence of prostate cancer 
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mortality reduction. Also, the controversy with the potential increase in high grade cancers 
could not be overlooked. Their conclusion was based on the fact that the risks of high-grade 
cancer were potentially real and could not be explained entirely by volume grade bias, 
increased sensitivity of PSA and DRE or removal of low-grade cancers. Finally, since the 
both REDUCE and the PCPT trials utilized end-of-study biopsies, the trial results were not 
yet generalizable to the US population. ODAC voted against the new indication for 
dutasteride (yes = 2, no = 14, abstain = 2) and against the new labeling for finasteride (yes = 
0, no = 17, abstain = 1).  
Due to ODAC’s ruling, the FDA does not currently support the use of 5-ARIs for prostate 
cancer chemoprevention. After the decision made by ODAC, a publicly funded clinical trials 
cooperative group, SWOG (Southwest Oncology Group), released a statement disagreeing 
with ODAC’s decision to not use 5-ARIs for the prostate cancer prevention.35 
Clearly, disagreement remains after the publication of the two trials. GlaxoSmithKline has 
subsequently announced that it is withdrawing applications for similar approval in other 
countries.36 More long term data is needed to help experts agree on a consensus although 
we doubt that any further trials will be done with these agents to prevent prostate cancer. 
And likely because the other trials mentioned above have been negative, future trials for 
chemoprevention of prostate cancer will be rare.  
3.5 Economic impact of prostate chemoprevention 
Current economic assessments for chemoprevention are based on varying assumptions that 
take into account data from the PCPT, treatment costs, and life expectancy. In addition, 
variations on the model include how the PCPT data is integrated into the model. For 
example, PCPT high grade disease can include projections based on the actual data set or 
based on a data set adjusted for biases.  
To be effective, chemoprevention for cancer should cost roughly $100,000 or less per life 
year (LY) saved due to low adoption rates when cost is greater than $100,000/yr and high 
when cost is less than $20,000/yr .37 Svatek et al used SEER data to estimate real world 
incidence and analyzed the cost-effectiveness of finasteride. Their group concluded that 
finasteride was too expensive at $578,000 to $1,107,000 USD per LY saved.38  
Subsequent studies supported that chemoprevention was too expensive and estimated the  
expense per LY saved at up to $1.6 million.39 However, an analysis on quality adjusted life-
years (QALYs) based on PCPT prevalence rates showed a lower cost per LY due to higher 
PCPT prevalence rates. This analysis demonstrated $122,000 per QALY saved.40 If 
finasteride is assumed to not increase the incidence of high grade cancers, then the analysis 
demonstrated $112,000 per QALY saved. Thus more patients benefit from chemoprevention. 
These analyses were based on the current price of finasteride at $66/month. If finasteride 
becomes less expensive, then the cost per QALY has the potential to drop significantly. 
Similarly, one study evaluated dutasteride based on the REDUCE study data and concluded 
that it too was not cost effective as a general chemopreventative agent.41 
Currently chemoprevention with either finasteride or dutasteride is not cost effective. The 
identification of a high risk subgroup would potentially decrease the cost to benefit ratio 
thus making chemoprevention feasible from an economic standpoint. In addition, 
decreasing the cost of either 5-ARI has the potential to make chemoprevention feasible. 
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4. Discussion  
Currently the only proven chemopreventative agents for prostate cancer are finasteride and 
dutasteride with up to a ~24% reduction in prostate cancer (24% PCPT, 23% REDUCE).  
However, as discussed earlier, the perceived risk of high grade cancers and the unclear long 
term benefit for low grade cancers has caused the ruling against the use of 5-ARI’s for 
chemoprevention. Reanalysis of the Prostate Cancer Prevention Trial (PCPT) does not 
support this ruling and suggests that high-grade cancer is not associated with finasteride 
therapy and that prostatectomy is the only definitive diagnosis for the evaluation for 
prostate cancer.42 In addition, the effects of PSA, DRE and prostate volume bias will 
continue to make interpretation of the data difficult.43 
It is important to note that as many of 30% of clinically insignificant cancers on first biopsy 
are then upstaged on second biopsy to become significant cancers. Consequently, the long 
term benefits of preventing low grade disease are uncertain.44 Also, by reducing the 
incidence of low grade disease, the potential for decreasing the “burden of treatment” is 
uncertain. But in the US environment where greater than 90% of men diagnosed with 
prostate cancer seek treatment, it is clear that individuals who have low grade cancer 
prevented will benefit.45 
Despite evidence from the PCPT and REDUCE trials, there does not appear to be a trend 
towards prescribing 5-ARIs for the prevention of prostate cancer. Approximately 64% of 
Urologists and 80% of primary care providers never prescribe finasteride for prostate cancer 
chemoprevention. Over half of Urologists reported concerns for inducing high grade 
tumors. In addition, half of the primary care physicians were not aware 5-ARIs could be 
used for chemoprevention.46 With the current ruling by ODAC, it is likely that physicians 
will trend away from prescribing 5-ARI medications for chemoprevention.  
Further analyses are required to pinpoint the subgroup population that will benefit most 
and the timing that is required to be effective. The PCPT revealed a high prevalence of 
prostate cancer, but no reliable markers were available to determine who would benefit 
most from biopsy or treatment. REDUCE prospectively collected samples to retrospectively 
analyze potential biomarkers but has not yet identified a subgroup that would yet benefit 
from dutasteride prevention.47 
In the current political environment, the adoption of 5-ARI medications is slim due to the 
uncertainty surrounding finasteride and dutasteride. Further analysis into subgroups of 
patients may reveal that 5-ARIs are clinically significant and economically available for at 
risk individuals. Maybe then, the benefits of 5-ARI medications will outweigh their 
uncertainty regarding high risk disease. In the meantime, investigations into new 
biomarkers, nutritional supplements and other pharmacologic agents may elicit a potential 
solution to the perplexing problem of primary prevention. 
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